
Kristen M. O'Dwyer, M.D.
Contact
About Me
Faculty Appointments
Associate Professor - Department of Medicine, Hematology/Oncology (SMD)
Credentials
Residency & Fellowship
Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center. 2006 - 2010
Residency, Internal Medicine, New York Presbyterian Hospital/Weill Cornell. 2005 - 2006
Internship, Internal Medicine, New York Presbyterian Hospital/Weill Cornell. 2004 - 2005
Internship, Pathology, National Cancer Institute/National Institute of Health. 2003 - 2004
Awards
Young Investigator Award. 2016
Wilmot Cancer Research Fellowship. 2010 - 2013
Young Investigator Award. 2009 - 2010
Clinical Scholars Biomedical Research Fellowship. 2007 - 2009
National Institutes of Health General Research Loan Repayment Program. 2003 - 2004
Howard Hughes Medical Institute Research Training Fellowship for Medical Students. 2002 - 2003
NIH Research Scholar, Cloister Program. 2000 - 2002
Medical Student Teaching Fellowship. Dept. of Physiology. 1998
Research
Clinical Trials
Lead Researcher: Kristen M O'Dwyer
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ...
Lead Researcher: Kristen M O'Dwyer
The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).
Lead Researcher: Kristen M O'Dwyer
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in diff...
Lead Researcher: Kristen M O'Dwyer
We will establish two prospective groups of patients with Acute Lymphoclastic Leukemia (ALL): "Cohort A" will be enrolled on the study at the time of diagnosis while "Cohort B" will be enrolled during maintenance chemotherapy.
Publications
Journal Articles
Optimal Approach to T-cell ALL. Hematology Am Soc Hematol Educ Program
O'Dwyer KM.
2022; 2022 (1):197-205.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R.
2021; Lancet 2021;398:491-502.
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
Sekeres MA; Guyatt G; Abel G; Alibhai S; Altman JK; Buckstein R; Choe H; Desai P; Erba H; Hourigan CS; LeBlanc TW; Litzow M; MacEachern J; Michaelis LC; Mukherjee S; O'Dwyer K; Rosko A; Stone R; Agarwal A; Colunga-Lozano LE; Chang Y; Hao Q; Brignardello-Petersen R.
2020; .
Treatment Strategies for Adolescent and Young Adult Patients with Acute Myeloid Leukemia
O'Dwyer KM; Freyer DR; and Horan JT.
2018; .
Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW
Blood.. 2016 September 29128 (13):1671-8. Epub 07/15/2016.
Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R
Bioorganic & medicinal chemistry.. 2016 September 124 (17):3876-3886. Epub 06/16/2016.
O'Dwyer KM, Advani AS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 February 2034 (6):533-8. Epub 12/23/2015.
Bennett, JM; Dsouza, KG; Patel, M; O'Dwyer KM.
Leukemia research reports. 2015; 4(1): 12-4.
Kolev JN, O'Dwyer KM, Jordan CT, Fasan R
ACS chemical biology.. 2014 January 179 (1):164-73. Epub 11/08/2013.
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL
Leukemia research.. 2013 December 37 (12):1622-7. Epub 09/08/2013.
Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT
The Journal of biological chemistry.. 2013 November 22288 (47):33542-58. Epub 10/02/2013.
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT
Cell stem cell.. 2013 March 712 (3):329-41. Epub 01/17/2013.
O'Dwyer K, Maslak P
Expert opinion on pharmacotherapy.. 2008 August 9 (11):1981-6. Epub 1900 01 01.
Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA
Endocrine-related cancer.. 2006 December 13 (4):1017-31. Epub 1900 01 01.
Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen Y, Bittner M, Strausberg RL, Riggins GJ, Wagner U, Kallioniemi OP, Trent JM, Morin PJ, Meltzer PS
Oncogene.. 2004 March 1823 (12):2264-74. Epub 1900 01 01.
Carr KM, Rosenblatt K, Petricoin EF, Liotta LA
Human genomics.. 2004 January 1 (2):134-40. Epub 1900 01 01.
Carr KM, Bittner M, Trent JM
Oncogene.. 2003 May 1922 (20):3076-80. Epub 1900 01 01.
Early results from a dioxin genome project.
Thomas, RS; Rank, DR; Jovanovich, S; Hogenesch, JB; Zastro, GM; Carr, KM; Bradfield, CA.
Toxicologist. 1999; : 307.
Molecular characterization of the murine HIF-1 alpha locus.
Luo, G; Gu, Y; Jain, S; Chan, WK; Carr, KM; Hogenesch, JB; Zastro, GM; Carr, KM; Bradfield, CA.
Gene Expressions. 1997; : 287-99.
Identification of palmitoylation sites within the L-type calcium channel beta-two subunit and effects on channel function.
Chien,AJ; Carr, KM; Shirokov, RE; Rios, E; Hosey, MM.
Journal of Biological Chemistry. 1996; : 26465-68.
Semin Hematol. The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis.
O'Dwyer K.
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Shah BD; Bishop MR; Oluwole OO; Logan AC; Baer MR; Donnellan WB; O'Dwyer KM; Holmes H; Arellano ML; Ghobadi A; Pagel JM; Lin Y; Cassaday RD; Park JH; Abedi M; Castro JE; DeAngelo DJ, Malone AK; Mawad R; Schiller GJ; Rossi JM; Bot A; Shen T; Goyal L; Jain RK; Vezan R; Wierda WG.
Blood. 2021 138(1):11-22.